$8 SHIPPING — free on U.S. orders over $60
Ardent Peps
Ardent PepsResearch Grade
Metabolic

RC-R

Investigational triple-receptor metabolic research peptide — the most potent weight-loss peptide currently under study.

For educational and research use only. Not intended for human or animal consumption. Always consult a qualified healthcare professional before starting any protocol.

Overview & mechanism

RC-R activates three metabolic receptor pathways. Adding the third (energy-expenditure) arm to the dual-incretin mechanism is thought to increase calorie burn in addition to reducing intake. Phase 2 research reported some of the largest weight reductions ever seen in this class at 48 weeks.

Research dose & half-life

Half-life:
~6 days
Research dose:
Research titration: 2 mg weekly, escalated by 2–4 mg every 4 wks up to 8–12 mg weekly. Alternative approach: start at 1 mg weekly, then increase by 0.5–2 mg every 4 weeks as tolerated. Subcutaneous.
Protocol notes:
Schedule: once weekly subcutaneous, same day/time each week; take with adequate hydration. Start/stop: begin at the lowest dose; increase only if no significant nausea, vomiting, or palpitations. Stop and seek guidance if severe GI symptoms, chest pain, or rapid heartbeat occur. Cautions: contraindicated in personal/family history of medullary thyroid carcinoma or MEN2; use caution with gallbladder disease, pancreatitis, or concurrent glucose-lowering agents.

Safety & side effects

Incretin effects: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue. The third receptor arm adds: increased heart rate, mild blood pressure elevation, and transient increases in fasting glucose or liver enzymes at higher doses. Serious: pancreatitis, gallbladder disease, dehydration/kidney injury, hypoglycemia with insulin/sulfonylureas. Same MTC/MEN2 contraindication as other incretin-class peptides. Avoid in pregnancy, active pancreatitis, and unstable cardiovascular disease. Investigational — long-term human safety is not yet established.

Deep dive

Why the triple-receptor mechanism matters

RC-R engages appetite/insulin signaling, insulin sensitivity and adipose handling, and an energy-expenditure pathway. That third arm is what differentiates it from RC-S and RC-T — it raises basal energy expenditure and mobilizes hepatic fat. In Phase 2 research at 48 weeks, mean weight reductions of ~24% at the 12 mg dose were the largest ever reported for this class.

Slow-titration ('microdosing') protocol

Many researchers use a slower ramp than the trial schedule: start at 1 mg weekly for 4 weeks, then increase by 0.5–2 mg every 4 weeks based on tolerance. This trades a few extra weeks for meaningfully less nausea, less muscle loss, and easier long-term adherence. Hold at the lowest dose that still produces appetite suppression rather than always chasing the ceiling.

Heart rate and blood pressure monitoring

Because of the added energy-expenditure receptor activity, RC-R can produce a modest resting heart rate increase (typically 3–10 bpm at higher doses) and small blood pressure shifts. Trend heart rate and BP weekly during escalations and hold or drop the dose if resting HR increases more than 15 bpm from baseline or palpitations occur.

Reconstitution notes

RC-R is typically reconstituted with bacteriostatic water to 4–10 mg/mL depending on vial size. Store the reconstituted vial refrigerated and use within roughly 28 days. Use the reconstitution calculator to convert your target weekly dose into units on an insulin syringe.

Frequently asked questions

How does RC-R compare to RC-T?

In separate Phase 2/3 research, the triple-receptor peptide at 12 mg produced roughly 24% mean weight loss at 48 weeks versus ~21% for the dual-receptor peptide at 15 mg at 72 weeks. The added receptor arm is credited with the larger effect, but RC-R is still investigational and long-term human safety data is limited.

Should I start at 2 mg or 1 mg weekly?

The trial schedule starts at 2 mg. Many researchers prefer starting at 1 mg to minimize first-dose nausea and blood pressure/heart rate changes, then increasing by 0.5–2 mg every 4 weeks. Either is reasonable — the slower ramp trades a few extra weeks for better tolerability.

What day of the week should RC-R be dosed?

Any consistent day works. Because peak nausea and appetite suppression typically appear 24–72 hours post-injection, many researchers dose Friday or Saturday so the peak lands over a lower-activity weekend.

Does RC-R need to be cycled?

There is no receptor-tolerance reason to cycle. Breaks are typically taken for planned life events or to reassess baseline weight/appetite. After breaks longer than 2–3 weeks, restart at 1–2 mg to re-acclimate the gut.

Can RC-R be stacked with BPC-157 or other peptides?

No known negative interactions with BPC-157, TB-500, or GHK-Cu. Do not stack with another incretin-class peptide (RC-S, RC-T) — the mechanisms overlap and side effects compound. Introduce one new peptide at a time so effects can be attributed cleanly.

Back to education library